Next Article in Journal
Feasibility of Administering Zoledronic Acid in Palliative Patients Being Cared for in the Community: Results of a Pilot Study
Previous Article in Journal
Diagnosis and Management of Hepatocellular Carcinoma: Results of a Consensus Meeting of The Ottawa Hospital Cancer Centre
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 17
Issue 2
10.3747/co.v17i2.422
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

One Year of Complete Clinical Response in a Metastatic Breast Cancer Patient Treated with a Combination of Lapatinib and Gemcitabine

by
J. M. Gasent Blesa
*,
J. Laforga Canales
and
V. Alberola Candel
Hospital de Dénia, Marinasalud, s/n 03700 Dénia Alacant, Partida de Beniadlà, Spain
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(2), 64-68; https://doi.org/10.3747/co.v17i2.422
Submission received: 2 January 2010 / Revised: 3 February 2010 / Accepted: 5 March 2010 / Published: 1 April 2010

Abstract

The treatment of metastatic breast cancer is challenging. We recently assisted in the development of targeted therapies (in combination with chemotherapy or as monotherapy) that have improved results for selected groups of patients. Lapatinib is a dual tyrosine kinase inhibitor that has shown efficacy in breast cancer. Consequently, its use has been approved, in combination with capecitabine, for the treatment of disease positive for the human epidermal growth factor receptor. Here, we present a case of complete clinical response to a combination of lapatinib and gemcitabine that was maintained for 1 year.
Keywords: breast cancer; lapatinib; gemcitabine; complete response breast cancer; lapatinib; gemcitabine; complete response

Share and Cite

MDPI and ACS Style

Gasent Blesa, J.M.; Laforga Canales, J.; Alberola Candel, V. One Year of Complete Clinical Response in a Metastatic Breast Cancer Patient Treated with a Combination of Lapatinib and Gemcitabine. Curr. Oncol. 2010, 17, 64-68. https://doi.org/10.3747/co.v17i2.422

AMA Style

Gasent Blesa JM, Laforga Canales J, Alberola Candel V. One Year of Complete Clinical Response in a Metastatic Breast Cancer Patient Treated with a Combination of Lapatinib and Gemcitabine. Current Oncology. 2010; 17(2):64-68. https://doi.org/10.3747/co.v17i2.422

Chicago/Turabian Style

Gasent Blesa, J. M., J. Laforga Canales, and V. Alberola Candel. 2010. "One Year of Complete Clinical Response in a Metastatic Breast Cancer Patient Treated with a Combination of Lapatinib and Gemcitabine" Current Oncology 17, no. 2: 64-68. https://doi.org/10.3747/co.v17i2.422

APA Style

Gasent Blesa, J. M., Laforga Canales, J., & Alberola Candel, V. (2010). One Year of Complete Clinical Response in a Metastatic Breast Cancer Patient Treated with a Combination of Lapatinib and Gemcitabine. Current Oncology, 17(2), 64-68. https://doi.org/10.3747/co.v17i2.422

Article Metrics

Back to TopTop